THURSDAY, Dec. 16 (HealthDay News) -- U.S. scientists have
unraveled the genetic code for the most common type of brain cancer
Gene sequencing reveals that this tumor, medulloblastoma, or MB,
possesses far fewer genetic abnormalities than comparable adult
The discovery that MB has five to 10 times fewer mutations than
solid adult tumors could further attempts to understand what
triggers the cancer and which treatment is most effective.
"The good news here is that for the first time now we've identified the broken genetic pieces in a pediatric cancer, and found that with MD there are only a few broken parts," said lead author Dr. Victor E. Velculescu, associate professor with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore.
"And that means it's potentially easier to intervene and to stop it," he said, likening the cancer to a train that's speeding out of control.
Velculescu and his colleagues, who report their findings in the
Dec. 16 online issue of
Science, say this is the first time genetic decoding has been applied to a non-adult cancer.
Each year this cancer strikes about 1 in every 200,000 children
younger than 15 years old. Before migrating through the patient's
central nervous system, MBs begin in the cerebellum portion of the
brain that is responsible for controlling balance and complicated
Focusing on 88 childhood tumors, the research team uncovered 225
tumor-specific mutations in the MB samples, many fewer than the
number found in adult tumors. This surprised the researchers, given
that prior work had not suggested a large genetic difference
between childhood and adult malignancies.
The discovery could help improve the way MB is classified and
treated. "We now have the pieces of the puzzle which are altered in
this particular tumor type," noted Velculescu. "And what we have to
do is figure out how these pieces can be put together and come up
with new avenues for targeted therapies that take advantage of
At least one expert, Dr. Isabelle M. Germano, director of the
brain tumor treatment program at Mount Sinai Medical Center in New
York City, agrees that the finding gives researchers a new leg up
on a killer disease.
"Theoretically this study -- which postulates that because there are fewer mutations it might be easier to target those mutations -- could raise hope for finding a more successful way of dealing with MB," Germano said.
"So this is an improvement in our understanding of what we're dealing with. And once we understand better the mechanisms at the base of this illness, it becomes more possible to develop treatment options ... or, if possible, even prevent it from occurring in the first place," she said.
While not a common disease, MB accounts for 10 to 20 percent of
all primary tumors among children, Germano said. "And outcomes have
actually been improving as we come to know more about it, with
five-year survival around 80 percent for patients older than 3.
"But for infants [the five-year survival rate] is just 30 percent," she said. "So at the present time mortality can be pretty high."
For more on medulloblastoma, visit the
American Society of Clinical Oncology.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.